Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

Highlights • A phase II trial of gefitinib with inserted cisplatin plus docetaxel therapy. • Patients with advanced non-small cell lung cancer harboring EGFR mutations were enrolled. • The median progression free survival (PFS) was 19.5 months and 5-year PFS rate was 22.0%. • The median survival tim...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-09, Vol.89 (3), p.287-293
Main Authors: Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamamoto, Noboru, Sekine, Ikuo, Kunitoh, Hideo, Kubota, Kaoru, Tamura, Tomohide, Ohe, Yuichiro
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Docetaxel
Drug Resistance, Neoplasm - genetics
Epidermal growth factor receptor mutation
Female
Gefitinib
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Middle Aged
Mutation
Neoplasm Grading
Neoplasm Staging
Non-small cell lung cancer
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Pulmonary/Respiratory
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Survival Analysis
Taxoids - administration & dosage
Treatment Outcome
Tyrosine kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • A phase II trial of gefitinib with inserted cisplatin plus docetaxel therapy. • Patients with advanced non-small cell lung cancer harboring EGFR mutations were enrolled. • The median progression free survival (PFS) was 19.5 months and 5-year PFS rate was 22.0%. • The median survival time was 48.0 months and 5-year survival rate was 36.5%. • The insertion of chemotherapy might prevent the acquired resistance to EGFR-TKIs.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2015.06.016